Skip to main content

Translational Research Institute

Translational Research Institute

Clinical Trials

Showing 19-27 out of 33 results.
NCT05047263

FIND-CKD: A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease.

Icon for trial | 21177 FIND-CKD: A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diab

Study Purpose: To determine the safety and efficacy of Finerenone along with standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease. To be enrolled in this study, you must m ...

NCT01843127

GILEAD: A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects with Type 2 Diabetes Mellitus, Followed by An Open-label, Single-dose, Exenatide Active-control Period

Icon for trial | GILEAD: A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects with Type 2 Diabetes Mellitus, Followed by An Open-label, Single-dose, Ex

The primary purpose of this study is to understand the reasons why Ranolazine may potentially treat patients with T2DM. Ranolazine has been shown to block glucagon and therefore results in a lowering of blood glucose levels. Th ...